section name header

Pronunciation ⬇

ri-MAN-ti-deen

Classifications ⬆ ⬇

Therapeutic Classification: antivirals

Indications ⬆ ⬇

REMS


Unlabeled Use:
  • Treatment of influenza A infection in children.

Action ⬆ ⬇

  • Diminishes replication of influenza A virus by inhibiting uncoating of the virus.
Therapeutic effects:
  • When given prophylactically, prevents infection with influenza A virus. When administered within 48 hr of onset of infections, decreases the duration of fever and other associated symptoms.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver; <25% excreted unchanged in urine.

Half-Life: 25 hr (range 13–65 hr).

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid6 hrN/A

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

EENT: tinnitus

GI: abdominal pain, anorexia, diarrhea, dry mouth, dyspepsia, nausea, vomiting

Neuro: agitation, depression, dizziness, fatigue, headache, impaired concentration, insomnia, SEIZURES

Resp: dyspnea

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Hepatic Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Flumadine

Code ⬆

NDC Code